UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington  D. C.  20549


FORM 8-K


CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934.


February 1, 2008

Date of Report (Date of Earliest Event Reported)


 

DNAPrint Genomics, Inc.

 

 

(Exact name of registrant as specified in charter)

 


Utah

 

0-31905

 

59-2780520

(State or other jurisdiction

of incorporation)

 

(Commission File Number)

 

(IRS Employer

 Identification No.)


 

1621 West University Parkway, Sarasota, FL  34243

 

 

(Address of principal executive offices)

 


 

(941) 366-3400

 

 

(Registrant’s Telephone Number, including Area Code)

 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



ITEM 8.01

OTHER EVENTS


On January 18, 2008, the Registrant entered into a nonbinding letter of intent with Nanobac Pharmaceuticals, Incorporated (“Nanobac”).  This letter of intent was amended on February 1, 2008. This letter of intent and amendment are filed with this 8-K.



ITEM 9.01

EXHIBITS


99.01  Non-binding letter of intent dated January 18, 2008 between Nanobac Pharmaceuticals, Incorporated and the Registrant.


99.02  Amendment dated February 1, 2008 to the non-binding letter of intent between Nanobac Pharmaceuticals, Incorporate and the Registrant.




SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


 

 

 

DNAPrint Genomics, Inc.

 

 

 

 

 

 

 

 

 

 

 

By:

/s/ Richard Gabriel

 

 

 

 

Richard Gabriel

 

 

 

 

Chief Executive Officer & President




DNAPrint Genomics (CE) (USOTC:DNAG)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024 Haga Click aquí para más Gráficas DNAPrint Genomics (CE).
DNAPrint Genomics (CE) (USOTC:DNAG)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024 Haga Click aquí para más Gráficas DNAPrint Genomics (CE).